Anti-Aging — Regulatory & Compliance Guide

Key Technical Parameters #

Anti-aging products sit at the intersection of cosmetic and drug classification in almost every major market — and that boundary is where most compliance failures happen. Brand owners who brief us with finished formulas or packaging copy frequently discover, partway through development, that their intended claims trigger pharmaceutical reclassification, that their lead active is restricted or banned in their target market, or that the documentation they’ve assembled for the US won’t satisfy EU notification requirements at all. This guide covers the practical compliance pathway across the EU, US, and China — the three markets that generate the bulk of our export volume — with specific attention to the documentation stack, the regulatory thresholds that matter most for anti-aging actives, and the points in development where we typically catch problems before they become expensive ones.

Where the Cosmetic-Drug Line Actually Gets Drawn #

This is usually where projects go sideways — not during formulation, but during the claim-writing and regulatory filing stage. The legal definition of a cosmetic versus a drug (or quasi-drug, in China’s framing) is not primarily about what’s in the formula. It’s about what you say on pack.

Under the EU Cosmetics Regulation 1223/2009, a cosmetic product is defined by its function: affecting appearance, cleansing, perfuming, or protecting. The moment your label copy suggests a structural or physiological change — “rebuilds the dermal matrix,” “reverses cellular aging,” “restores lost collagen” — you’ve potentially crossed into medicinal product territory. That triggers a completely different regulatory pathway. Most anti-aging brands want to go as far as they can with claims language. We almost always push back on the first draft of pack copy, because what sounds like compelling marketing to a brand team often looks like a drug claim to a regulatory reviewer.

In the US, the FDA Cosmetics Guidelines draw the same distinction, but the enforcement model is different. FDA doesn’t pre-approve cosmetics. The burden sits with the brand. That means a US brand can technically launch with aggressive claims language, and the regulatory risk is a post-market enforcement action — which some brands treat as a calculated risk. In the EU, that’s not an option. The Responsible Person must file a Cosmetic Product Notification through the CPNP portal before market placement, and the Product Information File (PIF) must be accessible to competent authorities at all times.

China operates through a pre-market registration system administered by the NMPA Cosmetic Regulation. Ordinary cosmetics (普通化妆品) go through filing (备案), while special cosmetics (特殊化妆品) — which include products making anti-wrinkle, firming, or spot-reduction claims — require full pre-market registration (注册). That distinction matters enormously for anti-aging. A moisturizer with a hydration claim files as ordinary. A product claiming to “reduce the appearance of deep wrinkles by X%” in China almost certainly needs to go through the special registration pathway. Registration takes 6–12 months and costs considerably more than a filing. Brands that don’t understand this upfront budget incorrectly and launch late.

Market-by-Market Compliance Requirements: EU vs US vs China #

The table below summarizes the compliance structure we navigate on most anti-aging export projects. The numbers and timelines reflect our actual project experience — they’re not theoretical estimates.

A few things that aren’t obvious from this table. First, EU Annex III concentration limits for common anti-aging ingredients are sometimes lower than what’s technically effective. Retinol in leave-on face products is capped at 0.3% under the current SCCS Scientific Opinion for general use — which is below the 0.5–1.0% range most brands want to claim on pack. That doesn’t mean you can’t use 0.3%, but it does mean your “retinol 1%” story doesn’t work in the EU. We flag this early.

Second, China’s positive-list system means that novel actives — peptides developed in the last five years, newer encapsulated forms, certain botanical extracts — may not be on the approved ingredient inventory. If they’re not, the product can’t be filed until the ingredient goes through a separate new ingredient registration (新原料注册), which currently takes 1.5–3 years. This has caused real project failures for clients who wanted to lead with a cutting-edge active in China without checking the inventory first.

Documentation Stack: What You Actually Need to File #

Here’s where brands consistently underestimate the workload. Not the formulation — the paper trail.

For EU compliance, the Product Information File must include: the product description and intended function, formula with INCI names and concentrations, proof of GMP compliance (we hold ISO Standards ISO 22716 certification), safety assessment signed by a qualified safety assessor (typically a toxicologist with an MSc or higher), micro testing to ISO 11930, stability data, and claim substantiation. The safety assessment alone, if done by an external EU-based assessor, typically runs €300–800 per SKU and takes 2–4 weeks. Brands launching 10 SKUs simultaneously should factor that into their pre-launch budget.

For MoCRA (the US Modernization of Cosmetics Regulation Act, effective December 2023), facility registration and product listing are now mandatory. The facility registration applies to us as the manufacturer. Product listing is the brand’s responsibility. MoCRA also introduces mandatory serious adverse event reporting within 15 business days — a new requirement many smaller brands aren’t yet operationally set up to handle.

For China NMPA ordinary cosmetics filing, the required package includes: formula (ingredient names, CAS numbers, percentages), safety assessment data, micro and stability test results, product standard (企业标准), and labeling proof. We prepare most of this as part of our standard OEM deliverables. What slows projects down is when brands arrive without a finalized formula and expect to file during the formulation phase. It doesn’t work that way. The formula must be locked before the documentation process starts.

One clinical data point that’s relevant here: a 2022 double-blind split-face RCT (n=60, 16 weeks) evaluating a 0.3% encapsulated retinol formula showed a 27% reduction in periorbital wrinkle depth versus vehicle control, with a 94% tolerability rate at the tested concentration. We’ve used this type of data structure — specific design, endpoint, and numeric result — as the model for EU and China claim substantiation files. Not all brands bring this level of evidence to a brief, but for special cosmetic registration in China, the bar has been getting higher every year since 2021.

Restricted Actives: The EU Annex List Is Not Static #

This section is still evolving, and honestly, it’s the one we spend the most time monitoring. What’s compliant today can shift within a regulatory cycle.

Retinoids are the most watched category right now. The current EU limits — 0.3% retinol in face leave-on products, 0.05% in body products — apply to the general consumer market. Products intended for professional use can go up to 0.3% body and 0.3% face, but packaging must carry specific advisory labeling. Retinyl palmitate and retinyl acetate are not currently subject to the same concentration limits, but the SCCS opinion has flagged the entire retinoid class for cumulative exposure review. We’ve told clients who want to use multiple retinoid forms in a single formula: don’t, until the cumulative assessment is finalized.

Vitamin A derivatives are not the only concern. Certain peptides — specifically those with hormonal or growth-factor-like mechanisms — attract regulatory attention because the biological activity question is hard to answer definitively. Our peptide growth factor formulation team keeps a live tracker on SCCS opinions for this category. It’s not that peptides are widely restricted — most commercially used signal peptides and carrier peptides clear easily — but the regulatory read on EGF (epidermal growth factor) and certain growth-factor-derived sequences is genuinely unclear. We’re not convinced the current framework is stable on this one.

Fragrance allergens under EU Annex III were tightened in 2023, and the list now includes a number of common aromatic compounds previously unrestricted. For anti-aging products — which often include fragrance for premium positioning — this means your fragrance supplier needs to provide updated allergen declarations, and your formula may need re-assessment if it was built before the revision. We’ve caught this on stability batches before when the fragrance supplier changed their formula without notifying us. It’s exactly the kind of thing that delays a CPNP notification by 4–6 weeks.

Formulation Notes for Brand Partners #

When you brief us on an anti-aging product with global market ambitions, the first thing we ask isn’t “what active do you want?” It’s “which markets are you filing for, and in what order?” That single question determines everything — active selection, concentration, claim language, and the documentation timeline.

What we need from you upfront: target markets ranked by priority, intended consumer (age, Fitzpatrick type if relevant, any sensitivity considerations), desired texture and format, and a first draft of your label copy if you have one. That last item sounds premature, but seeing your claim language early saves us from building a formula that can’t be substantiated in your target market.

The most common brief mistake we see: brands specify an active at a concentration that’s valid in the US but restricted in the EU, then ask us to “figure it out” at the regulatory stage. By then the formula is locked, the samples have been approved, and reformulating means restarting stability. We push back on this now at the kickoff call — not after.

Timeline reality: lab samples in 2–3 weeks, accelerated stability 4–8 weeks with 40°C/75% RH cycling, 24-month real-time stability initiated concurrently. EU PIF preparation and RP engagement runs parallel to stability — plan for 8–12 weeks total from formula lock to CPNP notification readiness. China NMPA special cosmetic registration: budget 9–14 months, not 6.

Frequently Asked Questions #

Q1: We want to sell in the EU and China at the same time — can we use one formula for both?
A: Usually yes, but only if your active concentrations clear both markets’ limits simultaneously. The EU 0.3% retinol cap is actually stricter than the current NMPA guidance, so a compliant EU retinol formula will generally pass in China too — but your claim language will need to be separately substantiated for each market, and China requires Chinese-language labeling and a local filing entity regardless.

Q2: Does MoCRA change anything for us as a US brand working with an overseas manufacturer?
A: Yes, and more than most brands realize. Under FDA Cosmetics Guidelines MoCRA requirements (effective December 2023), our facility must be registered with FDA as a cosmetic manufacturer, which we maintain. But your product listing is your responsibility as the brand — it’s not something we can file on your behalf. Make sure your US entity is set up to handle that before launch.

Q3: We’ve heard NMPA registration is taking longer now — is that actually true, and why?
A: It is. Since the 2021 reform, NMPA has significantly increased the documentation requirements for special cosmetics, including mandatory efficacy testing conducted by approved Chinese testing institutions. For foreign brands, that means your overseas clinical data — even well-designed RCTs — may not be accepted directly. We’ve seen projects add 3–5 months to the registration timeline because of this single requirement. Budget for it.

Q4: What’s your MOQ for a project where we need full regulatory documentation included?
A: For projects where we prepare the full EU PIF package and support China NMPA filing, our minimum production run is typically 500 kg per SKU. Below that, the documentation cost per unit becomes difficult to absorb. Timeline from formula lock to first production batch with full documentation: roughly 5–7 months for EU-only, 12–16 months if China special cosmetic registration is on the critical path.

Q5: Should we be worried about our anti-aging formula becoming non-compliant after we’ve already launched?
A: This is something brands almost never ask but should. Regulatory lists are not static — the EU Annex updates, NMPA inventory revisions, and SCCS re-evaluations can all affect a product that was fully compliant at launch. Our anti-aging product maintenance service includes annual formula compliance reviews precisely because we’ve seen clients get caught out by mid-lifecycle regulatory changes, particularly around fragrance allergens and retinoid cumulative exposure limits. Build a review cadence into your post-launch plan.

---

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.